What is the price of a box of Atrasentan on the market?

Atrasentan (atrasentan) is a new type of endothelin receptor antagonist, originally developed byAbbVie. It is mainly targeted at patients with primary immunoglobulin A nephropathy and is used to delay the deterioration of renal function. This drug reduces the contraction of renal blood vessels and inflammatory response by inhibiting the binding of endothelin-1 (ET-1) to its receptors, thereby protecting the glomerular filtration function and delaying the progression of renal damage. Compared with traditional kidney disease treatment drugs, atrasentan not only regulates blood pressure, but also reduces proteinuria levels and has a long-term protective effect on renal microcirculation. This mechanism makes it considered as one of the drugs with the potential to modify the disease process in patients with chronic kidney disease.

Atrasentan has been approved for marketing in some countries, especially in the European and American markets.The management of chronic kidney disease related to type 2 diabetes. Although atrasentan has been approved for marketing in China, it has not been officially sold on the market due to the short approval time and the channels have not yet been fully rolled out. Therefore, there is no specific retail price or medical insurance payment standard. In overseas markets, its price is relatively high. The price of 0.75 mg × 30 tablets is about US$13,054, which is equivalent to more than 90,000 RMB. Since this drug is an innovative drug and no generic version has yet been launched, the market price is still determined exclusively by the original drug.

From a pharmacological perspective, the clinical positioning of atrasentan is not just an antihypertensive drug, but an innovative treatment plan for systematically regulating intrarenal hemodynamics and fibrosis. Its long-term benefits in reducing proteinuria, slowing down glomerulosclerosis and reducing the risk of cardiorenal complications have been recognized in overseas studies. With the implementation of the rapid review mechanism for new drugs for rare diseases and kidney diseases by domestic regulatory authorities, atrasentan is expected to achieve formal sales and medical insurance negotiations in the future, and the price is expected to drop significantly by then.

Reference materials:https://www.vanrafia.com/